Financial & Legal Considerations for Life Sciences PartnershipsDecember 10-11 2019, Philadelphia, PA Sponsored by Dynamic Global Events |
Click Here to register $1896.00 |
Creating innovative life sciences, pharma and biotech mergers and partnership opportunities has never been more critical to organizational growth. As product offerings grow, the industry is being impacted by rapidly changing market conditions, pricing considerations, and legislative updates. Don’t miss the opportunity to learn from and network with leaders in pharma, life sciences, and M&A. Through a comprehensive agenda comprised of case studies and expert panels, you’ll gain timely insights into antitrust trends, what CFIUS (the Committee on Foreign Investment in the United States) could mean for your cross-border endeavors, due diligence best practices, and the mechanics of raising series funding. Meet and network with essential industry stakeholders in a collaborative setting. AGENDA Tuesday, December 10th, 2019 | Day 19:00 AM - 9:15 AM Chairperson’s Day 1 Opening Remarks9:15 AM - 12:30 PM Part 1: Planning & Raising Series Funding & Legal ImplicationsStart-ups or budding enterprises -- series funding is on your radar. Many NextGen therapeutic developers are finding great success in raising millions to make their respective marks. Laying the foundation for achieving financing is a difficult task but calculated-fundraising efforts are critical. Participants in this session will:
Ivan Kugener, MD MBA MSc - Vice President, Head of Global Portfolio Management - Global Strategic Excellence 12:30 PM - 1:30 PM Networking Lunch1:30 PM - 3:45 PM Part 2: Managing Pipeline Opportunity & Risk in a Mid-Size Pharmaceutical CompanyLearn how sharing risk and financial burdens with external partners strengthens your partnerships. This session will:
Ivan Kugener, MD MBA MSc - Vice President, Head of Global Portfolio Management - Global Strategic Excellence 3:45 PM - 4:15 PM Chairperson’s Day 1 Closing RemarksWednesday, December 11th, 2019 | Day 28:00 AM - 9:00 AM Networking Breakfast9:00 AM - 9:30 AM Chairperson’s Day 1 Recap and Day 2 Introduction9:30 AM - 10:15 AM KEYNOTE ADDRESS: Strategic Exits - Start from the Beginning!Although growth drivers in M&A transactions are well understood, the causes of unsuccessful outcomes are seldom discussed. This session will highlight:
David Sheppard - Managing Director Florence Joffroy-Black – CEO 10:15 AM - 10:30 AM Morning Networking & Refreshment Break10:30 AM - 11:15 AM CASE STUDY: Acquirers Share Their M&A ExperiencesM&A veterans will share their insights into financial and legal trends, market drivers and criteria for acquisition opportunities. Among the questions they will answer are:
Michael Hong - Chief Investment Officer and Portfolio Manager Jason Colgate - Managing Director of Private Equity Acquisitions 11:15 AM - 12:00 PM CASE STUDY: How Smaller Drug Companies Bring New Innovations from Trial to MarketThis presentation will disrupt how you think about bringing new drugs to market. Attendees will:
Bill Abajian - Chief Executive Officer, Restructuring, and Turn-Arounds 12:00 PM - 1:00 PM Networking Lunch 1:00 PM - 1:45 PM Intellectual Property Strategies that Close Transactions - Navigating the Legal Process & Attracting CapitalLife science companies can use intellectual property (IP) to make their businesses attractive for strategic partners or buyers. In this program, participants will:
Gregory Grissett - Intellectual Property Lawyer and Chair Intellectual Property Group 1:45 PM - 2:30 PM Mitigating Risk with Due Diligence Best PracticesDue diligence can make or break any deal. This presentation will cover:
Rahul Khara - Senior Director, Compliance and Commercial Counsel 2:30 PM - 3:00 PM Afternoon Networking & Refreshment Break3:00 PM - 3:45 PM CASE STUDIES: IPO, Venture Capital, & Legal Alternatives for Product, Portfolio & Market DevelopmentAttend this session to gain a greater understanding of the financing options available to sellers and buyers. These case studies will:
Bill Abajian - Chief Executive Officer, Restructuring, and Turn-Arounds Michael Hong - Chief Investment Officer and Portfolio Manager Jason Colgate - Managing Director of Private Equity Acquisitions 3:45 PM - 4:15 PM Open Forum Q&A |